UTHR · UNITED THERAPEUTICS Corp · Financials
$543.98
+2.36 (+0.44%)
At close · Oct 7
Return incl. dividend (before tax)
Market Cap
$20.39B
Shares
42.89M
Volume · Oct 7
17.78K
Avg daily vol (3M)
642.08K
Income-statement, balance-sheet and cash-flow figures from SEC filings, plus a debt profile anchored in the latest 10-K and updated by each 10-Q and debt exhibit.
Revenue
$3.18B
+10.6%
FY2025
Net Income
$1.33B
+11.7%
FY2025
Gross Margin
87.92%
-1.3pp
FY2025
Operating Margin
46.89%
-1pp
FY2025
Diluted EPS
$27.86
+13.1%
FY2025
Operating Cash Flow
$1.56B
+17.6%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | FY2027 (G) | TTM | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | FY2015 | FY2014 | FY2013 | FY2012 | FY2011 | FY2010 | FY2009 | FY2008 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| $4B | $3.15B | $3.18B | $2.88B | $2.33B | $1.94B | $1.69B | $1.48B | $1.45B | $1.63B | $1.73B | $1.6B | $1.47B | $1.29B | $1.12B | $916.08M | $743.18M | $592.9M | $358.88M | $281.5M | |
| — | $437.2M | $384.4M | $309.7M | $257.5M | $151.6M | $122.5M | $108.1M | $117.6M | $198.7M | $105.7M | $72.7M | $69M | $125.9M | $131.13M | $119.3M | $88.9M | $67.67M | $40.86M | $26.96M | |
| — | $2.72B | $2.8B | $2.57B | $2.07B | $1.78B | $1.56B | $1.38B | $1.33B | — | — | — | — | $1.15B | $975.82M | $786.83M | $652.19M | $524.03M | $316.78M | — | |
| — | — | 87.92% | 89.24% | 88.94% | 92.17% | 92.73% | 92.71% | 91.88% | — | — | — | — | 89.53% | 87.36% | 85.89% | 87.76% | 88.38% | 88.27% | — | |
| — | $551.5M | $550M | $481M | $408M | $322.9M | $540.1M | $357.7M | $1.18B | $357.9M | $264.6M | $147.6M | $245.1M | $242.5M | $299.35M | $173.39M | $180.02M | $165.31M | $120.37M | $239.18M | |
| — | $764M | $755.8M | $709.7M | $477.1M | $482.1M | $467M | — | — | $265.8M | $330.1M | $316.8M | $452.7M | $381.3M | $394.01M | $201.75M | $156.48M | $188.61M | $171.89M | $94.31M | |
| — | — | $900K | $900K | $300K | $100K | $100K | $200K | $200K | $100K | $500K | $600K | $1.1M | $1.4M | $2.6M | $2.1M | $1.7M | $1.6M | — | — | |
| — | $91.5M | $85.6M | $72.5M | $53.2M | $51.3M | $49.9M | $49.9M | $45.9M | $35.9M | $31M | $31.6M | $32.9M | $32.2M | $31.26M | $27.15M | $20.54M | $17.92M | $11.39M | $4.54M | |
| — | $1.75B | $1.69B | $1.5B | $1.14B | $956.6M | $1.13B | $889.7M | $1.64B | $822.4M | $910.4M | $537.1M | $766.8M | $749.7M | $824.49M | $494.43M | $425.4M | $421.59M | $333.12M | $363.55M | |
| — | $1.4B | $1.49B | $1.38B | $1.18B | $979.7M | $555.9M | $593.6M | -$187.6M | $805.4M | $814.9M | $1.06B | $699M | $538.8M | $292.5M | $421.65M | $317.78M | $171.31M | $25.76M | -$82.06M | |
| — | — | 46.89% | 47.86% | 50.91% | 50.6% | 32.98% | 40.02% | -12.95% | 49.48% | 47.23% | 66.41% | 47.69% | 41.82% | 26.19% | 46.03% | 42.76% | 28.89% | 7.18% | -29.15% | |
| — | $1.49B | $1.58B | $1.45B | $1.24B | $1.03B | $605.8M | $643.5M | -$141.7M | $841.3M | $845.9M | $1.09B | $731.9M | $571M | $323.76M | $448.79M | $338.32M | $189.23M | $37.15M | -$77.52M | |
| — | $12M | $19.5M | $42.9M | $59.3M | $32.4M | $18.6M | $23.5M | $44.2M | $13.9M | $9M | $3.9M | $4.7M | $17.6M | $18.06M | $16.64M | $21.37M | $19.71M | $12.88M | $11.44M | |
| — | $162.9M | $192M | $199.1M | $162.7M | $45.2M | $16.7M | $28.6M | $44.2M | $28.6M | $10.9M | $3.5M | — | — | $3.83M | $3.94M | $3.45M | $2.94M | $5.15M | $11.03M | |
| — | $171.2M | $221.4M | $162M | $89.4M | -$29.1M | $38M | $45.3M | $22.6M | -$46.5M | -$45.4M | -$1.5M | $345.4M | -$13.6M | -$13.6M | $19.03M | -$18.67M | -$16.16M | -$7.13M | -$1.67M | |
| — | -$200K | — | — | — | — | — | — | — | — | — | — | — | — | — | -$143K | -$119K | -$160K | -$141K | -$226K | |
| — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | — | -$7.69M | -$4.49M | -$1.6M | |
| — | $1.57B | $1.71B | $1.54B | $1.27B | $950.6M | $593.9M | $638.9M | -$165M | $758.9M | $769.5M | $1.06B | $1.04B | $525.2M | $278.9M | $440.67M | $299.12M | $155.15M | $18.62M | — | |
| — | $262.1M | $379.2M | $343.9M | $289.5M | $223.3M | $118.1M | $124.1M | -$60.5M | $169.7M | $351.6M | $346.5M | $392.8M | $185.1M | $104.34M | $136.23M | $81.87M | $43.95M | -$695K | -$34.39M | |
| — | $1.31B | $1.33B | $1.2B | $984.8M | $727.3M | $475.8M | — | -$104.5M | $589.2M | $417.9M | $713.7M | $651.6M | — | — | — | — | $105.92M | $19.46M | -$49.33M | |
| — | — | 41.94% | 41.53% | 42.31% | 37.56% | 28.23% | — | -7.21% | 36.2% | 24.22% | 44.64% | 44.45% | — | — | — | — | 17.86% | 5.42% | -17.52% | |
| — | — | — | — | — | $727.3M | $475.8M | $514.8M | -$104.5M | $589.2M | $417.9M | $713.7M | $651.6M | $340.1M | $174.56M | $304.44M | $217.87M | $105.92M | $19.46M | — | |
| — | $1.29B | $1.34B | $1.2B | $1.03B | $694.8M | $467M | $514.8M | -$110.8M | $600.9M | $415.1M | $717.3M | $647.9M | $336.5M | $176.33M | $300.37M | $216.16M | $101.06M | $21.06M | — | |
| USD/shares | — | $30.23 | $30.13 | $26.44 | $21.04 | $15.98 | $10.60 | $11.65 | -$2.39 | $13.54 | $9.50 | $16.29 | $14.17 | $7.06 | $3.49 | $5.84 | $3.81 | $1.89 | $0.37 | -$1.08 |
| USD/shares | — | $27.91 | $27.86 | $24.64 | $19.81 | $15.00 | $10.06 | $11.54 | -$2.39 | $13.39 | $9.31 | $15.25 | $12.72 | $6.28 | $3.28 | $5.71 | $3.67 | $1.78 | $0.35 | -$1.08 |
| shares | — | — | 44.3M | 45.2M | 46.8M | 45.5M | 44.9M | 44.2M | 43.8M | 43.5M | 44M | 43.8M | 46M | 48.2M | 50.08M | 52.09M | 57.16M | 56.14M | 53.31M | 45.8M |
| shares | — | — | 47.9M | 48.5M | 49.7M | 48.5M | 47.3M | 44.6M | 43.8M | 44M | 44.9M | 46.8M | 51.2M | 54.2M | 53.23M | 53.28M | 59.4M | 59.52M | 56.13M | 45.8M |
Italic rows are computed from reported lines — open a row's info icon for its formula. Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest. 3Y/5Y/10Y columns are trailing CAGR from the newest fiscal year; blank where an endpoint is missing or negative. (G): the company's own guidance — a (G) column is a guided period not yet reported; a G marker shows how the reported figure landed against the guided range. Non-GAAP-basis guidance (*) is shown as stated and never judged against GAAP actuals.
Capital Returned to Shareholders
Cash spent on share repurchases and dividends per fiscal year, as reported on the cash-flow statement. Across FY2011–FY2025: $4.07B in buybacks.
Debt Profile
Reported borrowing balances, repayment dates and agreement terms, with links to the underlying filings.
Reported debt balances
Each amount keeps its reported scope. Related balance-sheet measures appear under the borrowing they describe.
| Reported balance | As of | Amount | Source |
|---|---|---|---|
| Operating lease liabilities | 2022-09-30 | USD 12,200,000 | 10-Q filed 2022-11-02 |
Instrument and agreement coverage is incomplete. Additional filings are awaiting review.
Covenants
Covenant terms have not yet been verified for this profile.
The balance figures do not establish whether covenants apply or whether the company complies with them.
Loans, facilities and notes
The instrument breakdown is not yet verified. Read the debt note in the linked report for borrowing terms and maturity conditions.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Peer median 2.95×
EV/EBIT
—
Peer median 21.46×
P/E (TTM)
17.04×
Peer median 23.86×
Peer medians compare against the 21 similar-size Drug Manufacturers - Specialty & Generic companies (of 99 listed).
Valuation over time computed as of each quarter's filing date
Revenue Breakdown
Annual revenue as the company disaggregates it in its own XBRL filings. Years a component wasn't reported show a dash.
Share mode is each component's slice of the reported components that year — issuers rarely tag every revenue dollar, so slices need not sum to total revenue.
By Geography (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| United States | $3,037,000,000 | $2,739,700,000 | $2,202,200,000 | $1,814,100,000 | $1,564,200,000 | $1,412,100,000 | $1,323,200,000 | $1,528,200,000 |
| Non Us | $145,700,000 | $137,700,000 | $125,300,000 | $122,200,000 | $121,300,000 | $71,200,000 | $125,600,000 | $99,600,000 |
By Product & Service (USD)
| Component | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Tyvaso | $1,878,200,000 | $1,620,400,000 | $1,233,700,000 | $873,000,000 | $607,500,000 | $483,300,000 | $415,600,000 | $415,200,000 |
| TyvasoDPI | $1,292,500,000 | $1,033,600,000 | $731,100,000 | $158,300,000 | $0 | — | — | — |
| Nebulized Tyvaso | $585,700,000 | $586,800,000 | $502,600,000 | $714,700,000 | $607,500,000 | — | — | — |
| Remodulin | $526,800,000 | $538,100,000 | $494,800,000 | $500,200,000 | $513,700,000 | $516,700,000 | $587,000,000 | $599,000,000 |
| Orenitram | $496,900,000 | $434,300,000 | $359,400,000 | $325,100,000 | $306,100,000 | $293,100,000 | $225,300,000 | $205,100,000 |
| Unituxin | $226,800,000 | $238,700,000 | $198,900,000 | $182,900,000 | $202,300,000 | $122,900,000 | $113,700,000 | $84,800,000 |
| Adcirca | $30,000,000 | $23,800,000 | $28,900,000 | $41,300,000 | $55,900,000 | $67,300,000 | $107,200,000 | $323,700,000 |
| Product And Service Other | $24,000,000 | $22,100,000 | $11,800,000 | $13,800,000 | $0 | $0 | — | — |
Key facts
CIK
1082554
CUSIP
91307C102
13F (30d)
22 filings
18 filers
Visit website
Investor relations